Gastroenteropancreatic endocrine tumors

Research output: Contribution to journalReview article

Abstract

Gastroenteropancreatic endocrine tumors (GEP-NETs) are relatively uncommon; comprising approximately 0.5% of all human cancers. Although they often exhibit relatively indolent clinical courses, GEP-NETs have the potential for lethal progression. Due to their scarcity and various technical challenges, GEP-NETs have been understudied. As a consequence, we have few diagnostic, prognostic and predictive biomarkers for these tumors. Early detection and surgical removal is currently the only reliable curative treatment for GEP-NET patients; many of whom, unfortunately, present with advanced disease. Here, we review the genetics and epigenetics of GEP-NETs. The last few years have witnessed unprecedented technological advances in these fields, and their application to GEP-NETS has already led to important new information on the molecular abnormalities underlying them. As outlined here, we expect that "omics" studies will provide us with new diagnostic and prognostic biomarkers, inform the development of improved pre-clinical models, and identify novel therapeutic targets for GEP-NET patients.

Original languageEnglish (US)
Pages (from-to)101-120
Number of pages20
JournalMolecular and Cellular Endocrinology
Volume386
Issue number1-2
DOIs
StatePublished - Apr 5 2014

    Fingerprint

Keywords

  • ATRX
  • Carcinoid
  • DAXX
  • Epigenomics
  • Gastroenteropancreatic Neuroendocrine Tumor
  • Genomics

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Endocrinology

Cite this